Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Ariad Pharmaceuticals

Related ARIA
GNC, Southern Copper And Others Insiders Have Been Buying
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel

In a report published Monday, Jefferies & Company reiterated its Buy rating on Ariad Pharmaceuticals (NASDAQ: ARIA), but slightly lowered its price target from $28.00 to $27.00.

Jefferies noted, “With ponatinib approval for refractory/intolerant CML expected in U.S./EU in ~1Q13/3Q13, ARIA provided its commercial launch plan and a bit more details on ponatinib sales forecast, while refraining from providing profitability forecast (vs. our estimate of ~2016). Unlike ponatinib, AP26113 faces competition; we view its planned pivotal trial in ALK+ NSCLC in 2013 as important to maintain a competitive edge.”

Ariad Pharmaceuticals closed on Friday at $23.14.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters